2022
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki S, Bjork J, Blow F, Brenner L, Chen P, Desai S, Dieperink E, Fears S, Fuller M, Goodman C, Graham D, Haas G, Hamner M, Helstrom A, Hurley R, Icardi M, Jurjus G, Kilbourne A, Kreyenbuhl J, Lache D, Lieske S, Lynch J, Meyer L, Montalvo C, Muralidhar S, Ostacher M, Paschall G, Pfeiffer P, Prieto S, Przygodzki R, Ranganathan M, Rodriguez-Suarez M, Roggenkamp H, Schichman S, Schneeweis J, Simonetti J, Steinhauer S, Suppes T, Umbert M, Vassy J, Voora D, Wiechers I, Wood A. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA 2022, 328: 151-161. PMID: 35819423, PMCID: PMC9277497, DOI: 10.1001/jama.2022.9805.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPatient Health Questionnaire-9Usual care groupUsual carePharmacogenomic testingDrug-gene interactionsRemission rateMedication selectionCare groupDepressive disorderVeterans Affairs Medical CenterActive substance use disorderCo-primary outcomesPrescription of medicationsBetter clinical outcomesProportion of prescriptionsRemission of symptomsSubstance use disordersEligible patientsWeek 24Effective antidepressantSingle antidepressantClinical outcomesInitial treatmentQuestionnaire-9Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
Duarte-García A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS, Ross JS, Matteson EL, Shah ND. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings 2022, 97: 250-260. PMID: 35120693, PMCID: PMC9013005, DOI: 10.1016/j.mayocp.2021.08.026.Peer-Reviewed Original Research
2019
Antibiotic prescribing trends among US dermatologists in Medicare from 2013 to 2016
Kakpovbia E, Feng H, Feng PW, Cohen JM. Antibiotic prescribing trends among US dermatologists in Medicare from 2013 to 2016. Journal Of Dermatological Treatment 2019, 32: 70-72. PMID: 31122085, DOI: 10.1080/09546634.2019.1623372.Peer-Reviewed Original ResearchConceptsOral antibiotic prescriptionsOral antibioticsAntibiotic prescriptionsImportant public health issueAntibiotic prescription practicesAntibiotic prescribing trendsMedicare Part D Prescriber Public Use FilePart D Prescriber Public Use FileProportion of prescriptionsPublic health issuePrescribing trendsRetrospective reviewPrescription practicesOptimal careInflammatory diseasesMedicare patientsMedicare claimsElderly populationNumber of dermatologistsPublic Use FileUS dermatologistsDermatologistsHealth issuesMost antibioticsAdverse effects
2018
The Association of Industry Payments to Physicians with Prescription of Brand‐Name Intranasal Corticosteroids
Morse E, Fujiwara RJT, Mehra S. The Association of Industry Payments to Physicians with Prescription of Brand‐Name Intranasal Corticosteroids. Otolaryngology 2018, 159: 442-448. PMID: 29865931, DOI: 10.1177/0194599818774739.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdrenal Cortex HormonesConflict of InterestCross-Sectional StudiesDrug CombinationsDrug IndustryDrug UtilizationFemaleFluticasoneGift GivingHumansInterinstitutional RelationsMaleMometasone FuroatePhthalazinesPractice Patterns, Physicians'Prescription DrugsRetrospective StudiesConceptsIntranasal corticosteroidsProportion of prescriptionsPercentage of prescriptionsMagnitude of associationCorticosteroid prescriptionGeneral practitionersPhysician specialtyCorticosteroidsDrug timeBrand name prescriptionsPhysiciansPrescriptionRelative frequencyOtolaryngologistsNasonexAssociation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply